Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Non-Current Debt (2020 - 2025)

Myriad Genetics (MYGN) has disclosed Non-Current Debt for 4 consecutive years, with $119.9 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 202.78% to $119.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $119.9 million through Dec 2025, up 202.78% year-over-year, with the annual reading at $119.9 million for FY2025, 202.78% up from the prior year.
  • Non-Current Debt for Q4 2025 was $119.9 million at Myriad Genetics, roughly flat from $119.5 million in the prior quarter.
  • The five-year high for Non-Current Debt was $119.9 million in Q4 2025, with the low at $38.4 million in Q2 2023.
  • Average Non-Current Debt over 3 years is $57.0 million, with a median of $38.9 million recorded in 2024.
  • The sharpest move saw Non-Current Debt grew 1.04% in 2024, then surged 206.41% in 2025.
  • Over 3 years, Non-Current Debt stood at $38.5 million in 2023, then increased by 2.86% to $39.6 million in 2024, then soared by 202.78% to $119.9 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $119.9 million, $119.5 million, and $59.3 million for Q4 2025, Q3 2025, and Q1 2025 respectively.